The role of signal transduction in cancer treatment and drug resistance

European Journal of Surgical Oncology

Volumn 28, Issue 6, 2002, Pages 679-684

  Liem, A A ^a   Chamberlain, M P ^a   Wolf, C R ^a   Thompson, A M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Clinical trials; Drug resistance; Review; Signal transduction

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AMSACRINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIPODOPHYLLOTOXIN; EPIRUBICIN; ETOPOSIDE; GEFITINIB; LEFLUNOMIDE; MITHRAMYCIN; MITOMYCIN C; MITOXANTRONE; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; NAVELBINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; TENIPOSIDE; TOPOTECAN; TRASTUZUMAB; TRIMETREXATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

EID: 0036740804     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2002.1303     Document Type: Article

References (81)

1. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001; 7: 548-52.
2. Powis G. Signalling pathways as targets for anticancer drug development. Pharmacol Ther 1994; 62: 57-95.
3. Germann UA. P-glycoprotein - A mediator of multidrug resistance in tumour cells. Eur J Cancer 1996; 32A: 927-44.
4. Verweij J, de Jonge MJ. Achievements and future of chemotherapy. Eur J Cancer 2000; 36: 1479-87.
5. Wishart GC, Kaye SB. Is multidrug resistance relevant in breast cancer? Eur J Surg Oncol 1991; 17: 485-8.
6. Glazer RI, Rohlff C. Transcriptional regulation of multidrug resistance in breast cancer. Breast Cancer Res Treat 1994; 31: 263-71.
7. Stein U, Walther W, Lemm M, Naundorf H, Fichtner I. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo. Int J Cancer 1997; 72: 885-91.
8. Coley HM, Verrill MW, Gregson SE, Odell DE, Fisher C, Judson IR. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur J Cancer 2000; 36: 881-8.
9. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 1996; 32A: 912-20.
10. Goldstein LJ. MDR1 gene expression in solid tumours. Eur J Cancer 1996; 32A: 1039-50.
11. Maitra R, Halpin PA, Karlson KH, Page RL, Paik DY, Leavitt MO et al. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression. Biochem J 2001; 355: 617-24.
12. Aftab DT, Yang JM, Hait WN. Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug-resistant MCF-7 cells. Oncol Res 1994; 6: 59-70.
13. Loe DW, Deeley RG, Cole SP. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996; 32A: 945-57.
14. Fisher GA, Lum BL, Hausdorff J, Sikic BI. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996; 32A: 1082-8.
15. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000; 65: 95-106.
16. Benderra Z, Trussardi A, Morjani H, Villa AM, Doglia SM, Manfait M. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein. Eur J Cancer 2000; 36: 428-34.
17. Jensen PB, Sehested M, Langer SW, Hansen HH. Twenty-five years of chemotherapy in small cell lung cancer sends us back to the laboratory. Cancer Treat Rev 1999; 25: 377-86.
18. Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, et al. Phase I and pharmacokinetic study of the novel MDRI and MRPI inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 2001; 19: 3130-41.
19. Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, et al. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol 2000; 18: 1837-44.
20. Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J et al. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol 2001; 19: 1589-99.
21. Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets 2000; 1: 85-99.
22. Baekelandt M, Lehne G, Trope CG, Szanto I, Pfeiffer P, Gustavssson B et al. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol 2001; 19: 2983-93.
23. Budworth J, Gant TW, Gescher A. Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells. Br J Cancer 1997; 75: 1330-5.
24. Smith CD, Zilfou JT. Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem 1995; 270: 28145-52.
25. Mellado W, Horwitz SB. Phosphorylation of the multidrug resistance associated glycoprotein. Biochemistry 1987; 26: 6900-4.
26. Osborn MT, Chambers TC. Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 1996; 27: 30950-5.
27. Kang CD, Ahn BK, Jeong CS, Kim KW, Lee HJ, Yoo SD, et al. Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein. Exp Cell Res 2000; 256: 300-7.
28. Grant S, Jarvis WD. Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin Cancer Res 1996; 2: 1915-20.
29. Reddy KB, Krueger JS, Kondapaka SB, Diglio CA. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer 1999; 82: 268-73.
30. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-52.
31. Maemura M, Iino Y, Koibuchi Y, Yokoe T, Morishita Y. Mitogen-activated protein kinase cascade in breast cancer. Oncology 1999; 59: 37-44.
32. Hunter T. Oncoprotein networks. Cell 1997; 88: 333-46.
33. Tighe D, Moss R, Bennett D. Cell surface adrenergic receptor stimulation modifies the endothelial response to SIRS. Systemic Inflammatory Response Syndrome. New Horiz 1996; 4: 426-42.
34. Salituro FG, Germann UA, Wilson KP, Bemis GW, Fox T, Su MS. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr Med Chem 1999; 6: 807-23.
35. Marin V, Farnarier C, Gres S, Kaplanski S, Su MS, Dinarello CA, et al. The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. Blood 2001; 98: 667-73.
36. Larrivee JF, Bachvarov DR, Houle F, Landry J, Huot J, Marceau F. Role of the mitogen-activated protein kinases in the expression of the kinin BI receptors induced by tissue injury. J Immunol 1998; 160: 1419-26.
37. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-7.
38. McCormick F. Signalling networks that cause cancer. Trends Cell Biol 1999; 9: M53-6.
39. Chodosh LA, Gardner HP, Rajan JV, Stairs DB, Marquis ST, Leder PA. Protein kinase expression during murine mammary development. Dev Biol 2000; 219: 259-76.
40. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-65.
41. Davis RJ. MAPKs: new JNK expands the group. Trends Biochem Sci 1994; 19: 470-3.
42. Helmbrecht K, Zeise E, Rensing L. Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif 2000; 33: 341-65.
43. Fantz DA, Jacobs D, Glossip D, Kornfeld K. Docking sites on substrate proteins direct extracellular signal-regulated kinase to phosphorylate specific residues. J Biol Chem 2001; 276: 27256-65.
44. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM. Serine/threonine protein kinases and apoptosis. Exp Cell Res 2000; 256: 34-41.
45. Grammer TC, Blenis J. Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene 1997; 14: 1635-42.
46. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998; 17: 1395-413.
47. Dhanasekaran N, Premkumar Reddy E. Signaling by dual specificity kinases. Oncogene 1998; 17: 1447-55.
48. Crews CM, Alessandrini A, Erikson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 1992; 258: 478-80.
49. Brondello JM, Brunet A, Pouyssegur J, McKenzie FR. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J Biol Chem 1997; 272: 1368-76.
50. Langdon SP, Smyth JF. Inhibition of cell signalling pathways. Cancer Treat Rev 1995; 21: 65-89.
51. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-25.
52. Porter AC, Vaillancourt RR. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998; 17: 1343-52
53. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999; 286: 1738-41.
54. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001; 81: 153-208.
55. Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. Cancer Treat Rev 1999; 25: 271-7.
56. Sridhar R, Hanson-Painton O, Cooper DR. Protein kinases as therapeutic targets. Pharm Res 2000; 17: 1345-53.
57. Meric JB, Faivre S, Monnerat C, Adi Vago N, Le Chevalier T, Armand JP, et al. [Zd 1839 'Iressa']. Bull Cancer 2000; 87: 873-6.
58. Seymour L. Novel anti-cancer agents in development: exciting prospects and new challenges. Cancer Treat Rev 1999; 25: 301-12.
59. Morin MJ. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 2000; 19: 6574-83.
60. Hudes G. Signaling inhibitors in the clinic: new agents and new challenges. J Clin Oncol 1999; 17: 1093-4.
61. Eckhardt SG, Rizzo J, Sweeney KR, Cropp G, Baker SD, Kraynak MA et al. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol 1999; 17: 1095-104.
62. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-79.
63. Kerbel RS, Viloria-Petit A, Klement G, Rak J. 'Accidental' anti-angiogenic drugs, anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000; 36: 1248-57.
64. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. Ras activation in human breast cancer. Breast Cancer Res Treat 2000; 62: 51-62.
65. Broxterman HJ, Georgopapadakou N. Cancer research 2000: drug resistance, new targets and drugs in development. Drug Resist Updat 2000; 3: 133-138.
66. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997; 14: 2099-109.
67. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587-95.
68. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-30.
69. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000; 60: 5887-94.
70. Sebti SM, Hamilton AD. Farnesyltransferase and geranyl geranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000; 19: 6584-93.
71. Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001; 19: 1485-92.
72. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000; 19: 6594-9.
73. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001; 20: 147-55.
74. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5: 810-6.
75. Newton R, Cambridge L, Hart LA, Stevens DA, Lindsay MA, Barnes PJ. The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1 beta-dependent PGE(2) release via mechanistically distinct processes. Br J Pharmacol 2000; 130: 1353-61.
76. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
77. Martin-Blanco E. p38 MAPK signalling cascades: ancient roles and new functions. Bioessays 2000; 22: 637-45.
78. Hurst HC. Transcription factors as drug targets in cancer. Eur J Cancer 1996; 32A: 1857-63.
79. Buolamwini JK. Novel anticancer drug discovery. Curr Opin Chem Biol 1999; 3: 500-9.
80. Levitzki A. Targeting signal transduction for disease therapy. Med Oncol 1997; 14: 83-9.
81. Mihich E, Harlow E. Twelfth annual Pezcoller symposium: signaling cross-talks in cancer cells. Cancer Res 2000; 60: 7177-83.